These results generate renewed interest in the TGF-β pathway as an alternative therapeutic target for recurrent and metastatic disease and prompt a critical review of previous data underlying the use of TGF-β inhibitors in HNSCC. Here, TGFB1 is linked to metastatic neoplasm.